NOVEL TRIAZOLE COMPOUNDS Russian patent published in 2016 - IPC C07D401/14 C07D403/04 C07D405/14 C07D413/14 C07D417/14 C07D491/107 A61K31/4192 A61P25/00 

FIELD: pharmaceuticals.

SUBSTANCE: invention relates to compounds of formula (I), pharmaceutically acceptable salts and esters. Compounds of formula (I) have affinity and selectivity for GABA A α5 receptor. In formula X is N or CH; R¹, R² - C1-C7-alkyl, phenyl substituted by 1 halogen, wherein one of substituents R¹ and R² is an alkyl group; R³ - haloC1-C7-alkyl, nitro, -C(O) R⁴, -C(O) NR⁵R⁶; R⁴ - C1-C7-alkyl, hydroxy, C1-C7-alkoxy; R⁵ - hydrogen, C1-C7-alkyl, haloC1-C7 alkyl hydroxyC1-C7-alkyl, -(CH₂)_n-C3-C8 cycloalkyl, - (CH₂)_n- (4-6 membered heterocycloalkyl with 1 heteroatom selected from O), wherein heterocycloalkyl is optionally substituted with one C1-C7-alkyl group; n is an integer ranging from 0 to 1; R⁶ - hydrogen, C1-C7-alkyl; or R⁵ and R⁶ together with nitrogen to which they are attached form a bicyclic 7-membered heterocycloalkyl with additional heteroatom selected from O, 6-membered heterocycloalkyl with additional heteroatom selected from O, S, wherein heterocycloalkyl is optionally substituted by one or more oxo groups. Invention also relates to a pharmaceutical composition comprising a compound of invention in an effective amount, to a method for treating or preventing diseases associated with GABA A α5 receptor, use of compounds for preparation of medicaments and use of compounds for treating or preventing diseases associated with GABA A α5 receptor.

EFFECT: technical result is obtaining novel compounds having affinity and selectivity for GABA A α5 receptor.

23 cl, 1 tbl, 53 ex